Shares of Emergent BioSolutions EBS decreased in after-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose 15200.00% over the past year to $1.53, which beat the estimate of $1.12.
Revenue of $343,000,000 higher by 78.18% from the same period last year, which missed the estimate of $358,470,000.
Outlook
Emergent BioSolutions hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Apr 29, 2021
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/yvrb3cpe
Recent Stock Performance
Company's 52-week high was at $137.61
52-week low: $60.70
Price action over last quarter: down 41.53%
Company Profile
Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
